FeesSafety
Pluang+

Novo Nordisk raises cash flow guidance, boosts valuation on strong obesity drug growth and cost control.

Analyst Insights
17 Nov 2026, 23:06 WIB
Seeking Alpha
View Source
Bullish
Novo Nordisk raises cash flow guidance, boosts valuation on strong obesity drug growth and cost control.

Novo Nordisk has increased its free cash flow guidance to DKK 60–70 billion after reporting DKK 28.4 billion in Q3, with a gross margin improvement to 82.1%. The company's obesity drug is expanding internationally, and positive data on a lower-dose version along with an expected FDA decision support a potential early 2027 launch. Key risks include US injectable price erosion, Medicare pricing changes in 2027, and possible European generics by 2031. These factors reinforce Novo Nordisk's strong buy rating based on improving cash flow and disciplined cost management at a valuation of 10.89 times non-GAAP earnings.

Despite Novo Nordisk's strong free cash flow outlook and operational improvements, its stock price on Pluang is down 2.10% at USD 40.73 as of Nov 18, 2026 04:21 WIB, closer to its 52-week low of USD 35.29 than the high of USD 63.98. The market shows a heavy sell bias with 85% of orders to sell versus 15% to buy, indicating cautious sentiment despite the company's positive fundamentals and dividend yield of 4.32%.

More News (NVO)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App